Different effect of protein kinase B/Akt and extracellular signal-regulated kinase inhibition on trichostatin A-induced apoptosis in epithelial ovarian carcinoma cell lines

Molecular and Cellular Biochemistry

Volumn 353, Issue 1-2, 2011, Pages 1-11

  Jang, Eun Ra ^a   Kim, Yun Jeong ^a   Myung, Soon Chul ^b   Kim, Wonyong ^a   Lee, Chung Soo ^a  

^a Chung Ang University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

Akt and ERK inhibitors; Apoptosis related proteins; Epithelial ovarian adenocarcinoma cell lines; Trichostatin A

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN KINASE B; PROTEIN P53; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PROTEIN SECRETION; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLOTTING, WESTERN; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INOSITOL PHOSPHATES; MICROSCOPY, FLUORESCENCE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952102754     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0768-7     Document Type: Article

References (41)

1. Rasheed WK, Johnstone RW, Prince HM (2007) Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 16:659-678. doi:10.1517/13543784. 16.5.659 (Pubitemid 46729100)
2. Glaser KB (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74:659-671. doi: 10.1016/j.bcp.2007.04.007
3. Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H (2007) The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res 142:219-226. doi:10.1016/j.jss.2008.03.008 (Pubitemid 47418819)
4. Wu ZQ, Zhang R, Chao C, Zhang JF, Zhang YQ (2007) Histone deacetylase inhibitor trichostatin A induced caspase-independent apoptosis in human gastric cancer cell. Chin Med J 120: 2112-2118 (Pubitemid 350268159)
5. Sonnemann J, Hüls I, Sigler M, Palani CD, Le Hong TT, Völker U, Kroemer HK, Beck JF (2008) Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells. Oncol Rep 20:219-224
6. Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, Bader P, Beck JF (2006) Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 28:755-766
7. Arnold NB, Arkus N, Gunn J, Korc M (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13:18-26. doi:10.1158/1078-0432.CCR-06-0914 (Pubitemid 46121848)
8. Pan L, Lu J, Wang X, Han L, Zhang Y, Han S, Huang B (2007) Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 109:1676-1688. doi:10.1002/cncr.22585 (Pubitemid 46595705)
9. Dong G, Luo J, Kumar V, Dong Z (2010) Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am J Physiol Renal Physiol 298:F293-F300. doi:10.1152/ajprenal.00410.2009
10. Rosato RR, Grant S (2003) Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2:30-37
11. Duan H, Heckman CA, Boxer LM (2005) Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25:1608-1619. doi: 10.1128/MCB.25.5.1608-1619.2005 (Pubitemid 40280131)
12. Kumar KS, Sonnemann J, Beck JF (2006) Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells. Oncol Rep 16:1047-1052
13. Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3-10. doi:10.1002/1098-2388(200007/ 08) (Pubitemid 30439309)
14. Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062-1074
15. Graham K, Olson MF (2007) The ras signalling pathway as a target in cancer therapy. Recent Results Cancer Res 172:125-153
16. Grant S, Qiao L, Dent P (2002) Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 7:d376-d389
17. Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, Wan Y (2006) Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol 29:269-278
18. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A (2008) Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia 22:1449-1452. doi: 10.1038/sj.leu.2405079 (Pubitemid 352006093)
19. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Role of the Raf/MEK/ERK/pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263-1284. doi:10.1016/j.bbamcr.2006.10.001 (Pubitemid 47125967)
20. Smalley KS, Eisen TG (2002) Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int J Cancer 98:514-522. doi:10.1002/ijc.10213 (Pubitemid 34208551)
21. Bianco R, Melisi D, Ciardiello F, Tortora G (2006) Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 42:290-294. doi:10.1016/j.ejca.2005.07.034 (Pubitemid 43132883)
22. Westfall SD, Skinner MK (2005) Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol Cancer Ther 4:1764-1771. doi:10.1158/1535-7163.MCT- 05-0192 (Pubitemid 41685311)
23. Hoekstra AV, Ward EC, Hardt JL, Lurain JR, Singh DK, Buttin BM, Schink JC, Kim JJ (2008) Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol Oncol 108:609-618. doi:10.1016/j.ygyno.2007. 11.007
24. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63. doi:10.1016/0022-1759(83)90303-4
25. Andrisano V, Ballardini R, Hrelia P, Cameli N, Tosti A, Gotti R, Cavrini V (2001) Studies on the photostability and in vitro phototoxicity of Labetalol. Eur J Pharm Sci 12:495-504. doi: 10.1016/S0928-0987(00)00218-9 (Pubitemid 32170766)
26. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, Schulte-Hermann R (1992) Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc Natl Acad Sci 89:5408-5412
27. Tallarida RJ (1992) Statistical analysis of drug combinations for synergism. Pain 49:93-97. doi:10.1016/0304-3959(92)90193-F
28. Fivelman QL, Adagu IS, Warhurst DC (2004) Modified fixedratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother 48:4097-4102. doi:10.1128/AAC.48.11.4097-4102.2004 (Pubitemid 39434861)
29. Chipuk JE, Green DR (2006) Dissecting p53-dependent apoptosis. Cell Death Differ 13:994-1002. doi:10.1038/sj.cdd.4401908
30. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci 98:10833-10838. doi:10.1073/pnas.191208598 (Pubitemid 32878706)
31. Hu W, Kavanagh JJ (2003) Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4:721-729. doi:10.1016/S1470-2045(03)01277-4 (Pubitemid 37527207)
32. Camins A, Pallas M, Silvestre JS (2008) Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches. Methods Find Exp Clin Pharmacol 30:43-65. doi:10.1358/mf.2008.30.1.1090962 (Pubitemid 351397455)
33. Kelemen BR, Hsiao K, Goueli SA (2002) Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem 277:8741-8748. doi: 10.1074/jbc.M108459200 (Pubitemid 34968342)
34. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA (2003) Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 22:469-480
35. Barnett SF, Bilodeau MT, Lindsley CW (2005) The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr Top Med Chem 5:109-125 (Pubitemid 40514509)
36. Yoeli-Lerner M, Toker A (2006) Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5:603-605
37. Wood DE, Newcomb EW (2000) Cleavage of Bax enhances its cell death function. Exp Cell Res 256:375-382. doi:10.1006/excr.2000.4859 (Pubitemid 30244196)
38. Gao G, Dou QP (2000) N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome c release and apoptotic cell death. J Cell Biochem 80:53-72. doi:10.1002/1097- 4644(20010101)
39. Albihn A, Mo H, Yang Y, Henriksson M (2007) Camptothecin-induced apoptosis is enhanced by Myc and involves PKCd signaling. Int J Cancer 121:1821-1829. doi:10.1002/ijc.22866 (Pubitemid 47417303)
40. Cao X, Deng X, May WS (2003) Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. Blood 102:2605-2614. doi: 10.1182/blood-2003-01-0211 (Pubitemid 37193602)
41. Wiman KG (2006) Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 13:921-926. doi: 10.1038/sj.cdd.4401921